公开(公告)号：US20240342094A1

公开(公告)日：2024-10-17

申请号：US18740160

申请日：2024-06-11

申请人： Triastek, Inc.

发明人： Xiaoling LI

IPC分类号： A61K9/20 ,  A61K9/00 ,  A61K9/24 ,  A61K31/192

CPC分类号： A61K9/2031 ,  A61K9/0065 ,  A61K9/2027 ,  A61K9/2072 ,  A61K9/209 ,  A61K31/192

摘要： The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner.

公开(公告)号：US12109305B2

公开(公告)日：2024-10-08

申请号：US16303118

申请日：2017-05-26

申请人： Lyndra Therapeutics, Inc.

发明人： Andrew Bellinger ,  Rosemary Kanasty ,  Tyler Grant ,  Nupura Bhise ,  Robert Debenedictis ,  Jung Yang ,  Stephen Zale ,  John Klier

IPC分类号： A61K9/00 ,  A61F5/00 ,  A61K47/34 ,  A61L31/04 ,  A61L31/06 ,  A61L31/16

CPC分类号： A61K9/0065 ,  A61F5/0036 ,  A61K47/34 ,  A61L31/06 ,  A61L31/16 ,  A61L31/048 ,  A61L2300/602 ,  A61L2300/604 ,  A61L31/06 ,  C08L67/04 ,  A61L31/048 ,  C08L29/04

摘要： The invention provides gastric residence systems with specifically tailored architectures and methods for making such systems. The components of the gastric residence systems can be manufactured by three-dimensional printing or by co-extrusion. The ability to construct precise architectures for the systems provides excellent control over drug release, in vivo stability, and residence time of the systems.

公开(公告)号：US12064520B2

公开(公告)日：2024-08-20

申请号：US17694852

申请日：2022-03-15

申请人： Massachusetts Institute of Technology ,  The Brigham and Women's Hospital, Inc.

发明人： Carlo Giovanni Traverso ,  Alex G. Abramson ,  Ester Caffarel Salvador ,  Niclas Roxhed ,  Minsoo Khang ,  Taylor Bensel ,  Robert S. Langer

IPC分类号： A61K9/48 ,  A61B5/145 ,  A61B10/02 ,  A61B10/06 ,  A61J3/07 ,  A61K9/00 ,  A61K38/28 ,  A61M5/142 ,  A61M5/145 ,  A61M5/158 ,  A61M5/20 ,  A61M5/32 ,  A61M31/00 ,  A61M37/00 ,  A61N1/05 ,  A61N1/32 ,  A61N1/36

CPC分类号： A61K9/4808 ,  A61B5/14503 ,  A61B5/14539 ,  A61B10/02 ,  A61J3/07 ,  A61K9/0002 ,  A61K9/0012 ,  A61K9/0021 ,  A61K9/0065 ,  A61K9/0092 ,  A61K9/4866 ,  A61K38/28 ,  A61M5/14276 ,  A61M5/1454 ,  A61M5/158 ,  A61M5/2033 ,  A61M5/329 ,  A61M5/3295 ,  A61M31/002 ,  A61M37/0015 ,  A61M37/0069 ,  A61N1/325 ,  A61N1/36007 ,  A61B2010/0208 ,  A61B10/0233 ,  A61B10/06 ,  A61M2005/14284 ,  A61M2005/1581 ,  A61M2005/1585 ,  A61M2037/0023 ,  A61M2037/0053 ,  A61M2205/0238 ,  A61M2205/21 ,  A61M2210/1053 ,  A61M2210/106 ,  A61N1/0509

摘要： Components with relatively high loading of active pharmaceutical ingredients (e.g., drugs), are generally provided. In some embodiments, the component (e.g., a tissue interfacing component) comprises a solid therapeutic agent (e.g., a solid API) and a supporting material (e.g., a binder such as a polymer) such that the solid therapeutic agent is present in the component in an amount of greater than or equal to 10 wt % versus the total weight of the tissue interfacing component. Such tissue-interfacing components may be useful for delivery of API doses e.g., to a subject. Advantageously, in some embodiments, the reduction of volume required to deliver the required API dose as compared to a liquid formulation permits the creation of solid needle delivery systems for a wide variety of drugs in a variety of places/tissues (e.g., tongue, GI mucosal tissue, skin) and/or reduces and/or eliminates the application of an external force in order to inject a drug solution through the small opening in the needle. In some cases, a physiologically relevant dose may be present in a single tissue interfacing component (e.g., having a relatively high API loading).

公开(公告)号：US12053606B2

公开(公告)日：2024-08-06

申请号：US17007086

申请日：2020-08-31

申请人： Celero Systems, Inc.

发明人： Benjamin D. Pless ,  Daniel Bacher

IPC分类号： A61M31/00 ,  A61K9/00 ,  A61K9/48 ,  A61K31/485 ,  A61P25/36

CPC分类号： A61M31/00 ,  A61K9/0065 ,  A61K9/4808 ,  A61K31/485 ,  A61P25/36 ,  A61M2205/18 ,  A61M2205/3303 ,  A61M2205/3306 ,  A61M2205/3523 ,  A61M2205/3553 ,  A61M2205/50 ,  A61M2205/52 ,  A61M2210/1042 ,  A61M2230/04 ,  A61M2230/06 ,  A61M2230/20 ,  A61M2230/30 ,  A61M2230/42 ,  A61M2230/50 ,  A61M2230/63 ,  A61M2230/65

摘要： An opioid overdose rescue device is provided that includes an ingestible capsule. Within the ingestible capsule is a non-refillable drug dispenser comprising an opioid antidote and at least one sensor configured to detect at least one physiological parameter indicative of an opioid overdose. A controller is also contained within the ingestible capsule and is operatively coupled to the drug dispenser and the least one sensor. The controller is configured to receive a signal detected by the least one sensor of the at least one physiological parameter to actuate release of the opioid antidote from the drug dispenser into the intestine of the patient upon a determination that the at least one physiological parameter falls outside a threshold value or range for the at least one physiological parameter indicating that an opioid overdose has been detected.

公开(公告)号：US20240252483A1

公开(公告)日：2024-08-01

申请号：US18289331

申请日：2022-05-04

申请人： Lyndra Therapeutics, Inc.

发明人： Nupura BHISE ,  Jeffrey KATSTRA ,  David ALTREUTER

IPC分类号： A61K31/485 ,  A61K9/00 ,  A61K9/14

CPC分类号： A61K31/485 ,  A61K9/0019 ,  A61K9/006 ,  A61K9/0065 ,  A61K9/146

摘要： Provided are gastric residence systems comprising at least one co-extruded drug-eluting component comprising a carrier polymer, buprenorphine or a salt thereof, and naloxone or a salt thereof, and a rate-modulating release film coating the at least one co-extruded drug-eluting component. The gastric residence systems comprising at least one co-extruded drug-eluting component are configured to be maintained within a stomach of a human body for at least 48 hours and to release buprenorphine for at least 48 hours, such that the at least one co-extruded drug eluting component with the rate-modulating release film is configured to release at least 10% of the buprenorphine or the salt thereof after the first 24 hours of residence within the stomach and at least 10% of the naloxone or the salt thereof after the first 24 hours of residence within the stomach.

公开(公告)号：US11992552B2

公开(公告)日：2024-05-28

申请号：US15782021

申请日：2016-12-07

申请人： Lyndra Therapeutics, Inc.

发明人： Andrew Bellinger ,  Rosemary Kanasty ,  Tyler Grant ,  Colin Gardner

IPC分类号： A61M9/00 ,  A61K9/00 ,  A61K9/14 ,  A61K9/20 ,  A61K47/34 ,  A61K47/46 ,  A61M31/00 ,  C08G18/12 ,  C08G18/42 ,  C08G18/73

CPC分类号： A61K9/0065 ,  A61K9/146 ,  A61K9/20 ,  A61K47/34 ,  A61K47/46 ,  A61M31/002 ,  C08G18/12 ,  C08G18/4202 ,  C08G18/4277 ,  C08G18/73 ,  C08G18/12 ,  C08G18/42

摘要： The invention provides gastric residence systems with configurations and geometrical dimensions that allow for improved shelf life during prolonged storage, and optimal residence properties when the systems are deployed in the stomach of a patient.

公开(公告)号：US11964120B2

公开(公告)日：2024-04-23

申请号：US18056387

申请日：2022-11-17

申请人： CLEXIO BIOSCIENCES LTD.

发明人： Avshalom Ben Menachem ,  Ilan Zalit

IPC分类号： A61M31/00 ,  A61K9/00 ,  A61J3/07

CPC分类号： A61M31/002 ,  A61K9/0065 ,  A61J3/07 ,  A61M2210/1053

摘要： Provided herein are gastroretentive dosage forms (GRDFs) for extended retention in a human stomach, comprising a body comprising at least two arms, the body configured to transform between a collapsed configuration for ingestion, an expanded configuration for retention within the stomach and a disassembled configuration wherein after a predetermined time period has elapsed, the GRDF disassembles into at least two parts such that each of the disassembled parts of the GRDF is sized for exiting the stomach; and, an erodible insert comprising a therapeutic agent, a diagnostic agent, an electronical device, or a combination thereof.

公开(公告)号：US11957785B2

公开(公告)日：2024-04-16

申请号：US17346874

申请日：2021-06-14

申请人： Intelgenx Corp.

发明人： Rodolphe Obeid ,  Nadine Paiement ,  Erick Gonzalez-Labrada

IPC分类号： A61K9/00 ,  A61K31/05 ,  A61K31/352 ,  A61K36/185 ,  A61K45/06 ,  A61K47/10 ,  A61K47/12 ,  A61K47/20 ,  A61K47/26 ,  A61K47/32 ,  A61K47/34 ,  A61K47/36 ,  A61K47/42 ,  A61K47/44 ,  A61K47/46

CPC分类号： A61K9/006 ,  A61K31/05 ,  A61K31/352 ,  A61K36/185 ,  A61K45/06 ,  A61K47/10 ,  A61K47/12 ,  A61K47/20 ,  A61K47/26 ,  A61K47/32 ,  A61K47/34 ,  A61K47/36 ,  A61K47/42 ,  A61K47/44 ,  A61K47/46 ,  A61K9/0065 ,  A61K31/352 ,  A61K2300/00 ,  A61K31/05 ,  A61K2300/00

摘要： An orally administered dosage form that facilitates delivery of an agent locally in the buccal cavity for a sustained period of time includes mucoadhesive particles that are made of at least a mucoadhesive material combined with the agent, and which are dispersed in a disintegrating film. The dosage form is capable of delivering an agent to a patient at the desired oral mucosa site over an extended period of time while reducing patient discomfort or annoyance associated with conventional sustained release mucoadhesive films that must reside on the oral mucosa during the period of sustained release.

公开(公告)号：US20230416489A1

公开(公告)日：2023-12-28

申请号：US18367636

申请日：2023-09-13

申请人： OXFORD MEDICAL PRODUCTS LIMITED

发明人： Anthony John FITZPATRICK ,  Xue MIN ,  Jan Tadeusz CZERNUSZKA

IPC分类号： C08J9/36 ,  A61F5/00 ,  A61K9/00 ,  A61K9/28 ,  A61K9/48 ,  C08J9/00 ,  C08J3/075 ,  C08J3/24

CPC分类号： C08J9/36 ,  C08J2439/06 ,  A61K9/0065 ,  A61K9/284 ,  A61K9/286 ,  A61K9/4816 ,  C08J9/0028 ,  C08J9/0061 ,  C08J3/075 ,  C08J3/246 ,  C08G2210/00 ,  C08G2230/00 ,  C08J2205/022 ,  C08J2207/10 ,  C08J2305/04 ,  C08J2305/08 ,  C08J2339/06 ,  C08J2371/02 ,  C08J2405/08 ,  A61F5/0003

摘要： The invention relates to novel a high-volume swelling hydrogel which comprises a plurality of pores which are defined by an interpenetrating network, and/or a semi-interpenetrating network and/or simple cross-linked arrangement of a plurality of one or more species of hydrophilic polymers, optionally together with one or more biocompatible polymers and optionally together with one or more plasticising agents, characterised in that at least some of the pores are at least partially collapsed and/or flattened, and further characterised in that the interpenetrating network and/or semi-interpenetrating network and/or cross-linked arrangement which defines the collapsed and/or flattened pores is substantially unbroken. The invention also relates to a process for preparing such hydrogels, and to their use as an appetite suppressant.

公开(公告)号：US20230398066A1

公开(公告)日：2023-12-14

申请号：US18034004

申请日：2021-11-01

申请人： Triastek, Inc.

发明人： Feihuang DENG ,  Yu ZHENG ,  Xiaoling LI ,  Senping CHENG

IPC分类号： A61K9/00 ,  A61K9/48 ,  B33Y80/00 ,  B33Y10/00

CPC分类号： A61K9/0065 ,  A61K9/4808 ,  B33Y80/00 ,  B33Y10/00

摘要： Provided herein are drug dosage forms having a swellable component, which alone or in conjugation with one or more other components of the drug dosage forms expand the overall size of the drug dosage form in the stomach. The drug dosage forms are configured to be retained in the stomach for an extended period of time based on this increase in size of the drug dosage form in the stomach (e.g., retained in the stomach for a period of at least about 24 hours). The drug dosage forms described herein are formulated to release a drug during at least a portion of the stomach residency period. In other aspects, also provided are methods of designing, methods of making, such as using three-dimensional printing, and methods of delivering a drug to an individual, wherein such methods are associated with the drug dosage forms described herein.